SarcoMedUSA INC. was formed in Texas in 2017 to determine if Pulmozyme could improve Pulmonary Sarcoidosis. The company is nearing a final license agreement for Tigerase. Tigerase is approved and SarcoMedUSA will conduct a sponsored Pulmonary Sarcoidosis study in a University hospital that specializes in Sarcoidosis treatment.

Additionally, the company has an option on a no-alpha IL-2 mutein drug for certain cancers. SarcoMedUSA is working with Roswell Park Cancer Center in New York. There are final toxicology studies being completed in humanized mice studies which are ongoing and in our lab. The drug has been used in the Cuban clinic whereby two (2) of twelve (12) patients with advanced cancer had partial remission.

SarcoMed has assembled a nationally recognized team of drug development experts to move SM001 (alidornase) into the clinic. In 2021, our team was able to successfully complete a Pre-IND meeting with the Pulmonary Division of the FDA, which granted us orphan drug status.

Pulmonary Sarcoidosis is a significant market opportunity, with potential to generate over a billion dollars in annual revenue and help address a significant unmet need for the world wide patient population. SarcoMed is also exploring additional indications for SM001 such as Adult Respiratory Distress Syndrome, Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.